Subsequent decreasing rates of OS and PFS point to the challenge of long-term CAR T-Cell efficacy and durability of treatment.

Significant improvements seen in overall and disease-free survival, and reduction seen in all-cause, cancer-specific mortality.

Investigators developed a genomic score to assess potential survival benefits in patients with neuroendocrine neoplasms treated with immunotherapy.

In this study, researchers evaluated patterns of practice-reported screening for pain and depression as well as patient-reported receipt of assistance for these conditions.

These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.

Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.

The American Association for Cancer Research has released its annual Cancer Progress Report, highlighting the recent progress in cancer research. Keith Flaherty, M.D., chair of the AACR Cancer ...

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

Researchers analyzed the domain coverage and clinical application of screening tools used to assess palliative care needs in oncology.

These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.

In the MATCH trial, researchers assessed mindfulness-based cancer recovery and tai chi/qigong for individuals with cancer who were suffering from distress after treatment.